Quick Takeaways
- Daphne Karydas has 3 issuer positions tracked on this page.
- Estimated disclosed ownership value: $155,000.
- Recent insider filing activity is available below.
Insider Trading & Ownership of Daphne Karydas
- Location
- Waltham, MA
- Summary
- The estimated net worth of Daphne Karydas is at least $155,000 dollars as of 02 Apr 2026. Daphne Karydas is the Director of Mineralys Therapeutics, Inc. and owns shares of Mineralys Therapeutics, Inc. (MLYS) stock worth about $155K.
- Signature
- /s/ Adam Levy, Attorney-in-fact
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Daphne Karydas and return when a new Insider Trading filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean.
What Changed
- Largest disclosed position: Mineralys Therapeutics, Inc. ($155,000).
- Past-year value change for that position: -$764,797.
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Source Evidence
Filed on Form 4
See Original Filing
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
Ownership of Daphne Karydas
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| MLYS | Mineralys Therapeutics, Inc. | Director | $155,000 | -$764,797 | -83% | 31 Mar 2026 |
| CMPS | COMPASS Pathways plc | Director | 12 Jun 2025 | |||
| LOGC | LogicBio Therapeutics, Inc. | Director | 16 Nov 2022 |
Insider Transactions Reported by Daphne Karydas:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.